Alpa Laboratories (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Alpa Laboratories Limited |
|||
|
Price: ₹103.68 (+0.06%) | ||
| 52 Week Low: ₹86.31 52 Week High: ₹144.50 |
|||
| Market Capital: 236.54 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Alpa Laboratories Share Price Target For 2025
- 1.1.1: Alpa Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Alpa Laboratories Share Price Target For 2026
- 1.2.1: Alpa Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Alpa Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Alpa Laboratories Brief Company Overview
- 4: Alpa Laboratories Financial Performance
- 4.0.1: Is Alpa Laboratories A Good Buy For Long Term?
Alpa Laboratories, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 362.7% returns in 5-year with 14.9% profit margin, making it a potential Multibagger.
To predict the Alpa Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Alpa Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Alpa Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alpa Laboratories shares in 2025, see the table below.
Alpa Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 110.17 (+6.25%) | Fibonacci Extension Level 23.60% |
| 2025 Target 2 | 109.0 (+5.13%) | Price Action: 25 Mar 2025 Low |
| 2025 Target 1 | 107.81 (+3.98%) | Price Action: Jun 2025 High |
| Current Price | 103.68 | Alpa Laboratories's share price as of 18 Jul 2025 |
| Stop Loss 1 | 101.6 (-2%) | Price Action: Sep 2024 Low |
| Stop Loss 2 | 99.89 (-3.66%) | Price Action: 19 Jun 2025 High |
| Stop Loss 3 | 98.87 (-4.63%) | Price Action: 20 Jun 2025 High |
Short-Term Technical Outlook
Current Technical Position: Alpa Laboratories is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹102.77 serves as the nearest technical reference point.
Historical Returns: 3-month: -2.64% | 6-month: -14.85% | 1-year: +19.26%
Alpa Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Alpa Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alpa Laboratories shares in 2026, see the table below.
Alpa Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 156.54 (+50.98%) | Price Action: Chart |
| 2026 Target 2 | 153.62 (+48.16%) | Price Action: Chart |
| 2026 Target 1 | 152.1 (+46.7%) | Fibonacci Extension Level 64.90% |
| Current Price | 103.68 | Alpa Laboratories's share price as of 18 Jul 2025 |
| Stop Loss 1 | 92.0 (-11.27%) | Price Action: Jun 2024 High |
| Stop Loss 2 | 90.94 (-12.29%) | Fibonacci Retracement Level 71.80% |
| Stop Loss 3 | 89.3 (-13.87%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Alpa Laboratories is currently trading at 29.9% of its 52-week range (₹86.31 - ₹144.5).
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +19.26% | 3-year: +71.11% | 5-year: +362.71%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Alpa Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹103.68 | ||
| 2025 | ₹144.40 | +39.27% | ₹146.57 |
| 2026 | ₹193.81 | +34.21% | ₹196.72 |
| 2027 | ₹288.72 | +48.97% | ₹293.05 |
| 2028 | ₹408.37 | +41.44% | ₹414.50 |
| 2029 | ₹570.45 | +39.68% | ₹579.01 |
| 2030 | ₹726.87 | +27.42% | ₹737.77 |
| 2031 | ₹959.12 | +31.95% | ₹973.51 |
| 2032 | ₹1,246.49 | +29.96% | ₹1,265.19 |
| 2033 | ₹1,640.90 | +31.64% | ₹1,665.51 |
| 2034 | ₹2,251.68 | +37.22% | ₹2,285.46 |
| 2035 | ₹2,971.03 | +31.94% | ₹3,015.60 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Alpa Laboratories Brief Company Overview
Alpa Laboratories Limited: A Renowned Pharmaceutical Company Established in 1967, Alpa Laboratories Limited is a reputable pharmaceutical manufacturer based in India. The company specializes in producing and distributing a diverse range of pharmaceutical products for human...
and veterinary use. Key Products and Services: Ethical, generic, and over-the-counter products Injections, tablets, capsules, eye and ear drops, ointments, creams, and gels Anti-infectives, analgesics, and cardiovascular drugs Market Presence: Alpa Laboratories has a strong market presence in India, distributing its products through various channels including distributors, retail chemists, and hospitals. The company also exports its products to numerous countries across South America, Africa, Asia, Russia, Ukraine, and Kazakhstan. Commitment to Quality: Alpa Laboratories is committed to providing high-quality pharmaceutical products. The company adheres to stringent manufacturing standards and quality control measures to ensure the safety and efficacy of its products.Alpa Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 236.54 Crore | Market valuation of Alpa Laboratories's shares. |
| Revenue (TTM) | 108.73 Crore | Total revenue generated by Alpa Laboratories over the past twelve months. |
| Net Income (TTM) | +16.24 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -0.06% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +14.93% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-15.7% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+68% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
3.45 | Company's total debt divided by total shareholder equity. |
| Total Debt | 5.24 Crore | Sum of Alpa Laboratories's current & long-term financial obligations. |
| Total Cash | 92.85 Crore | Total amount of liquid funds available to Alpa Laboratories. |
| Beta | 1.03 | Beta is greater than 1 indicating that the Alpa Laboratories's price is more volatile than the market. |
Is Alpa Laboratories A Good Buy For Long Term?
Alpa Laboratories, a small-cap stock with a market capitalization of ₹236.54 crore, shows strong growth potential. While Q1 2024-25 revenue decreased by 15.7% quarter-over-quarter, a healthy profit margin of 14.93% and significant year-over-year earnings growth of 68% are positive indicators. Impressive past performance—51.90% return in the last 12 months and 338.11% over five years—suggests considerable long-term potential. However, its small size introduces higher risk. Considering the data, Alpa Laboratories could be a good buy for long-term investors with a moderate to high-risk tolerance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
